12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ibrutinib: Preliminary Phase II data

Preliminary data from an open-label Phase II trial in 70 patients with either activated B cell (ABC) subtype or germinal center ( GC) subtype DLBCL showed that once-daily 560 mg oral ibrutinib produced an ORR of 23%. In patients with the ABC subtype (n=29), ibrutinib produced 5 complete responses...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >